Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy

Aduhelm’s successor is now weeks away from its PDUFA date — and several advocacy groups are arguing for the reversal of a controversial CMS policy.

The groups, including the Azheimer’s Association and a number of doctors and medical professionals, are advocating for CMS to reconsider its January announcement that restricts the reimbursement of Aduhelm and other anti-amyloid monoclonal antibodies for Alzheimer’s disease to patients enrolled in CMS-approved, randomized controlled trials.